Table 1B

Randomised clinical trials of bDMARDs and tsDMARDs in combination with methotrexate compared with methotrexate alone in methotrexate-naïve patients with RA with disease duration >1 year

Mechanism of actionbDMARD or tsDMARDYear of publicationRA disease duration% of patients achieving remission in the combination arm% of patients achieving remission in the methotrexate monotherapy armTime-pointCorticosteroid use
TNF inhibitionInfliximab (ASPIRE)202004<3 years21.2015.00Week 54~38% of patients, ≤10 mg/day prednisone
TNF inhibitionAdalimumab (PREMIER)162005<3 years43.0021.001 year~33% of patients, mean dose prednisolone 6.5 mg/day
TNF inhibitionEtanercept (COMET)172008<2 years50.0028.00Week 52~50%, <1 mg/day
TNF inhibitionGolimumab (GO-BEFORE)232009~3 years38.0028.00Week 24~67% of patients (<10 mg/day)
IL6-R blockadeTocilizumab (FUNCTION)252015<2 years45.0015.00Week 24~40% of patients
B-cell depletionRituximab (IMAGE)192010≤4 years31.0013.00Week 52≤10 mg/day
JAK/STAT inhibitionTofacitinib (ORAL Start)262014~3 years14.607.606 monthsNA
JAK/STAT inhibitionBaricitinib (RA begin)272017~1.5 years40.0024.00Week 2436% of patients
Costimulation inhibitorAbatacept (AGREE)182009<2 years41.1023.3012 months~35% of patients, mean dose 7 mg/day
  • bDMARDs, biologic DMARDs; DMARDs, disease-modifying antirheumatic drugs; JAK/STAT, Janus Kinase/ Signal Transducer and Activator of Transcription proteins; NA, not available; TNF, tumor necrosis factor; tsDMARDs, targeted synthetic DMARDs.